Doctors at the Mayo Clinic have reported dramatic improvements in patients with stiff person syndrome following an experimental treatment. The trial, which utilized CAR-T cell therapy, showed that individuals who previously struggled with basic movement were able to resume daily activities and even return to work.
Stiff person syndrome is a rare autoimmune disorder that attacks the central nervous system. It causes severe muscle rigidity and painful spasms that can disable patients. Despite decades of research, no cure existed until this recent study, which published its findings in the journal Jama Neurology.
Experimental Treatment Restores Mobility
The therapy used in the trial is a form of immunotherapy already established in oncology. It involves extracting a patient’s own T cells and engineering them to target and destroy disease-causing cells. In this case, the modified cells were designed to attack the specific immune responses driving the neurological damage.
Dr. Anastasia Zekeridou, a neurologist at Mayo Clinic, noted the unusual extent of recovery observed in the study. She stated that while existing treatments might ease symptoms, they rarely allow patients to return to their previous level of function. The early results from this trial suggest a potential shift in how such conditions are managed.
Jonathan Walden, a participant in the study, described a complete reversal of his condition. Before the treatment, he required assistance from family members for walking and daily tasks. After receiving the CAR-T therapy, he reported having no further episodes of the disease.
“I can go to work every single day. I can do everything I did before. I go hunting; I can go fishing,” Walden said. His experience highlights the potential for the therapy to restore quality of life for those with this debilitating condition.
Broader Implications for Autoimmune Disease
Another patient, Shari St Germain, had suffered from severe leg cramps, falls, and muscle rigidity. Following the treatment, she experienced a steady improvement in her mobility. She recounted walking on a treadmill for seven minutes, an activity she had not been able to perform prior to the therapy.
Dr. Sean Pittock, chair of the department of neurology at Mayo Clinic, emphasized that this success could extend beyond stiff person syndrome. He suggested that the approach might offer hope for other immune-mediated neurologic conditions where effective treatments are currently limited.
The condition gained public attention when singer Céline Dion announced her diagnosis in December 2022. She described how the disease affected every aspect of her daily life, including her ability to sing. Her public disclosure helped raise awareness about the severity of the disorder.
Experts outside the trial have also reacted positively to the findings. Yasmin Sheikh, head of policy and public affairs at Anthony Nolan, a blood cancer charity, noted that the research provides further evidence that CAR-T cell therapies could have applications beyond blood cancer. She described the development as offering new hope to people living with other conditions.
While the results are promising, researchers caution that more work is needed to determine if these improvements will be sustained over time. The trial represents a significant step forward in understanding how to treat rare autoimmune diseases of the nervous system.
Source: The Guardian
